Deutsch English Français

Contact

EP1851245

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP1851245

EP1851245 - ANTIBODIES AGAINST INTERLEUKIN-1 BETA [Right-click to bookmark this link]
Status	No opposition filed within time limit Status updated on 16.08.2013 Database last updated on 08.10.2024
Most recent event Tooltip	17.07.2015	Lapse of the patent in a contracting state New state(s): HU, LU	published on 19.08.2015 [2015/34]
Applicant(s)	For all designated states Amgen Fremont Inc. One Amgen Center Drive Thousand Oaks, CA 91320-1799 / US
	[2012/44]
Former [2007/45]	For all designated states Amgen Fremont Inc. 6701 Kaiser Drive Fremont, CA 94555 / US
Inventor(s)	01 / GREEN, Larry 464 Hill Street San Francisco, California 94114 / US
	02 / FAGGIONI, Raffaella 634 Windmill Lane Pleasanton, California 94566 / US
	03 / FOORD, Orit 712 Cayman Lane Foster City, California 94404 / US
	04 / KLAKAMP, Scott, L. 1026 Dolphin Common Fremont, California 94536 / US
	05 / SENALDI, Giorgio 6534-f Cottonwood Circle Dublin, California 94568 / US
	06 / SCHNEIDER, Amy, K. 8160 Holanda Lane Dublin, California 94568 / US
	[2008/08]
Former [2007/45]	01 / GREEN, Larry 464 Hill Street San Francisco, California 94114 / US
	02 / FAGGIONI, Raffaella 634 Windmill Lane Pleasanton, California 94566 / US
	03 / FOORD, Orit 712 Cayman Lane Foster City, California 94404 / US
	04 / KLAKAMP, Scott, L. 1160 Chopin Terrace, 301 Fremont, California 94538 / US
	05 / SENALDI, Giorgio 6534-f Cottonwood Circle Dublin, California 94568 / US
	06 / SCHNEIDER, Amy, K. 8160 Holanda Lane Dublin, California 94568 / US
Representative(s)	Paemen, Liesbet R.J., et al De Clercq & Partners cvba Edgard Gevaertdreef 10 a 9830 Sint-Martens-Latem / BE
	[2012/41]
Former [2008/45]	Paemen, Liesbet R.J., et al De Clercq, Brants & Partners E. Gevaertdreef 10 A 9830 Sint-Martens-Latem / BE
Former [2007/45]	Brants, Johan P.E., et al De Clercq, Brants & Partners c.v. Edgard Gevaertdreef 10 a B-9830 Sint-Martens-Latem / BE
Application number, filing date	06718993.6	19.01.2006
	[2007/45]
	WO2006US02011
Priority number, date	US20050647643P	26.01.2005 Original published format: US 647643 P
	US20050753800P	22.12.2005 Original published format: US 753800 P
	[2007/45]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	WO2006081139
	Date:	03.08.2006
	Language:	EN
	[2006/31]
	Type:	A2 Application without search report
	No.:	EP1851245
	Date:	07.11.2007
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 03.08.2006 takes the place of the publication of the European patent application.
	[2007/45]
	Type:	B1 Patent specification
	No.:	EP1851245
	Date:	10.10.2012
	Language:	EN
	[2012/41]
Search report(s)	International search report - published on:	US	15.02.2007
	(Supplementary) European search report - dispatched on:	EP	14.04.2008
Classification	IPC:	C07K16/24	[2012/16]
	CPC:	C07K16/245 (EP,US); A61P19/10 (EP); A61P29/00 (EP); A61P35/02 (EP); A61P35/04 (EP); A61P9/10 (EP); (+) A61K2039/505 (EP,US); C07K2317/21 (EP,US); C07K2317/34 (EP,US); C07K2317/56 (EP,US); C07K2317/565 (EP,US); C07K2317/567 (EP,US); C07K2317/76 (EP,US); C07K2317/92 (EP,US); Y10S424/801 (EP,US); Y10S530/867 (EP,US) (-)
	Former IPC [2007/45]	C07K16/00, A61K39/395, A61K39/00
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR [2007/45]
Title	German:	ANTIKÖRPER GEGEN INTERLEUKIN-1-BETA	[2007/45]
	English:	ANTIBODIES AGAINST INTERLEUKIN-1 BETA	[2007/45]
	French:	ANTICORPS DIRIGÉS CONTRE L'INTERLEUKINE-1 BETA	[2007/45]
Entry into regional phase	24.08.2007	National basic fee paid
	24.08.2007	Search fee paid
	24.08.2007	Designation fee(s) paid
	24.08.2007	Examination fee paid
Examination procedure	24.08.2007	Amendment by applicant (claims and/or description)
	24.08.2007	Examination requested [2007/45]
	05.05.2008	Despatch of a communication from the examining division (Time limit: M06)
	05.11.2008	Reply to a communication from the examining division
	19.08.2009	Despatch of a communication from the examining division (Time limit: M06)
	01.03.2010	Reply to a communication from the examining division
	20.07.2010	Despatch of a communication from the examining division (Time limit: M02)
	20.09.2010	Reply to a communication from the examining division
	27.10.2010	Despatch of a communication from the examining division (Time limit: M03)
	15.12.2010	Reply to a communication from the examining division
	30.04.2012	Communication of intention to grant the patent
	28.08.2012	Fee for grant paid
	28.08.2012	Fee for publishing/printing paid
Divisional application(s)	EP10183582.5 / EP2361933
	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 05.05.2008
Opposition(s)	11.07.2013	No opposition filed within time limit [2013/38]
Fees paid	Renewal fee
	10.01.2008	Renewal fee patent year 03
	14.01.2009	Renewal fee patent year 04
	13.01.2010	Renewal fee patent year 05
	14.01.2011	Renewal fee patent year 06
	11.01.2012	Renewal fee patent year 07
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	HU	19.01.2006
	AT	10.10.2012
	BE	10.10.2012
	CY	10.10.2012
	CZ	10.10.2012
	DK	10.10.2012
	EE	10.10.2012
	FI	10.10.2012
	LT	10.10.2012
	LV	10.10.2012
	NL	10.10.2012
	PL	10.10.2012
	RO	10.10.2012
	SE	10.10.2012
	SI	10.10.2012
	SK	10.10.2012
	TR	10.10.2012
	BG	10.01.2013
	GR	11.01.2013
	IE	19.01.2013
	LU	19.01.2013
	MC	31.01.2013
	IS	10.02.2013
	PT	11.02.2013
	[2015/34]
Former [2015/32]	AT	10.10.2012
	BE	10.10.2012
	CY	10.10.2012
	CZ	10.10.2012
	DK	10.10.2012
	EE	10.10.2012
	FI	10.10.2012
	LT	10.10.2012
	LV	10.10.2012
	NL	10.10.2012
	PL	10.10.2012
	RO	10.10.2012
	SE	10.10.2012
	SI	10.10.2012
	SK	10.10.2012
	TR	10.10.2012
	BG	10.01.2013
	GR	11.01.2013
	IE	19.01.2013
	MC	31.01.2013
	IS	10.02.2013
	PT	11.02.2013
Former [2014/07]	AT	10.10.2012
	BE	10.10.2012
	CY	10.10.2012
	CZ	10.10.2012
	DK	10.10.2012
	EE	10.10.2012
	FI	10.10.2012
	LT	10.10.2012
	LV	10.10.2012
	NL	10.10.2012
	PL	10.10.2012
	RO	10.10.2012
	SE	10.10.2012
	SI	10.10.2012
	SK	10.10.2012
	BG	10.01.2013
	GR	11.01.2013
	IE	19.01.2013
	MC	31.01.2013
	IS	10.02.2013
	PT	11.02.2013
Former [2013/37]	AT	10.10.2012
	BE	10.10.2012
	CY	10.10.2012
	CZ	10.10.2012
	DK	10.10.2012
	EE	10.10.2012
	FI	10.10.2012
	LT	10.10.2012
	LV	10.10.2012
	NL	10.10.2012
	PL	10.10.2012
	RO	10.10.2012
	SE	10.10.2012
	SI	10.10.2012
	SK	10.10.2012
	BG	10.01.2013
	GR	11.01.2013
	MC	31.01.2013
	IS	10.02.2013
	PT	11.02.2013
Former [2013/35]	AT	10.10.2012
	BE	10.10.2012
	CY	10.10.2012
	CZ	10.10.2012
	DK	10.10.2012
	EE	10.10.2012
	FI	10.10.2012
	LT	10.10.2012
	LV	10.10.2012
	NL	10.10.2012
	PL	10.10.2012
	SE	10.10.2012
	SI	10.10.2012
	SK	10.10.2012
	BG	10.01.2013
	GR	11.01.2013
	IS	10.02.2013
	PT	11.02.2013
Former [2013/34]	AT	10.10.2012
	BE	10.10.2012
	CY	10.10.2012
	DK	10.10.2012
	FI	10.10.2012
	LT	10.10.2012
	LV	10.10.2012
	NL	10.10.2012
	PL	10.10.2012
	SE	10.10.2012
	SI	10.10.2012
	BG	10.01.2013
	GR	11.01.2013
	IS	10.02.2013
	PT	11.02.2013
Former [2013/31]	AT	10.10.2012
	BE	10.10.2012
	CY	10.10.2012
	FI	10.10.2012
	LT	10.10.2012
	LV	10.10.2012
	NL	10.10.2012
	PL	10.10.2012
	SE	10.10.2012
	SI	10.10.2012
	GR	11.01.2013
	IS	10.02.2013
	PT	11.02.2013
Former [2013/28]	BE	10.10.2012
	CY	10.10.2012
	FI	10.10.2012
	LT	10.10.2012
	LV	10.10.2012
	NL	10.10.2012
	PL	10.10.2012
	SE	10.10.2012
	SI	10.10.2012
	GR	11.01.2013
	IS	10.02.2013
	PT	11.02.2013
Former [2013/24]	BE	10.10.2012
	CY	10.10.2012
	FI	10.10.2012
	LT	10.10.2012
	LV	10.10.2012
	NL	10.10.2012
	PL	10.10.2012
	SE	10.10.2012
	SI	10.10.2012
	GR	11.01.2013
	IS	10.02.2013
Former [2013/23]	CY	10.10.2012
	FI	10.10.2012
	LT	10.10.2012
	LV	10.10.2012
	NL	10.10.2012
	PL	10.10.2012
	SE	10.10.2012
	SI	10.10.2012
	IS	10.02.2013
Former [2013/22]	FI	10.10.2012
	LT	10.10.2012
	NL	10.10.2012
	SE	10.10.2012
	SI	10.10.2012
	IS	10.02.2013
Former [2013/21]	LT	10.10.2012
	SE	10.10.2012
	SI	10.10.2012
Former [2013/20]	LT	10.10.2012
	SI	10.10.2012
Former [2013/11]	SI	10.10.2012
Documents cited:	Search	[X]WO0153353 (NOVARTIS AG [CH], et al) [X] 1-4,10,19,24-28 * page 5 - page 21 *;
		[X]WO0216436 (NOVARTIS AG [CH], et al) [X] 1-5,19,24,25,27,28 * the whole document *;
		[X]WO03010282 (LILLY CO ELI [US], et al) [X] 1,2,4-6,19,24,25,27,28 * page 2 - page 45 *;
		[X]US2003026806 (WITTE ALISON [US], et al) [X] 1-6,19,24,25,27,28 * the whole document *;
		[X]WO2004067568 (APPLIED MOLECULAR EVOLUTION [US], et al) [X] 1,2,4-6,19,24,25,27,28 * page 3, line 22 - page 35, line 14 *;
		[X]WO2004072116 (CELLTECH R&D LTD [GB], et al) [X] 1,2,4,19,24,25,27,28 * page 2, line 8 - page 24, line 4 *;
		[A]WO2004106377 (CELLTECH R&D LTD [GB], et al) [A] * the whole document *;
		[X] - JACKSON J R ET AL, "In Vitro Antibody Maturation Improvement of a High Affinity, Neutralizing Antibody Against IL-1Beta", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, (19950401), vol. 154, no. 7, ISSN 0022-1767, pages 3310 - 3319, XP000941315 [X] 1,2,5,19 * the whole document *
		[A] - BODER ERIC T ET AL, "Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, (20000926), vol. 97, no. 20, ISSN 0027-8424, pages 10701 - 10705, XP002185398 [A] * the whole document * DOI: http://dx.doi.org/10.1073/pnas.170297297
		[A] - GREEN L L, "Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, (19991210), vol. 231, no. 1-2, ISSN 0022-1759, pages 11 - 23, XP004187631 [A] * the whole document * DOI: http://dx.doi.org/10.1016/S0022-1759(99)00137-4
		[A] - DRAKE A W ET AL, "Characterizing high-affinity antigen/antibody complexes by kinetic- and equilibrium-based methods", ANALYTICAL BIOCHEMISTRY, ACADEMIC PRESS, SAN DIEGO, CA, US, (20040501), vol. 328, no. 1, ISSN 0003-2697, pages 35 - 43, XP004501899 [A] * the whole document * DOI: http://dx.doi.org/10.1016/j.ab.2003.12.025
	International search	[X]US2004063913 (GRAM HERMANN [DE], et al);
		[X] - MARIETTE, "Ig lambda chain V region-human", GENBANK, (19950106), Database accession no. (S30525), XP003007460

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 35p